Startup profile · funding coverage
Truemed funding, valuation and investors
Lets consumers use HSA/FSA funds on evidence-based preventive health products via Letters of Medical Necessity.
Keep track of Truemed
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$34M · December 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$34M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Overview
Truemed enables consumers to purchase eligible preventive health and wellness products using tax-advantaged HSA and FSA funds. The company partners with merchants and facilitates Letters of Medical Necessity (LMNs) from licensed providers where regulations require documentation. In December 2025, Andreessen Horowitz Bio + Health led a $34M Series A with Bessemer Venture Partners and Box Group participating. Truemed reported more than 3,000 merchant partners and approximately 3x year-over-year revenue growth entering the round. The company sits at the intersection of consumer wellness commerce and healthcare payment compliance.
Why Truemed is interesting
Preventive spend is mostly post-tax — a16z Bio+Health led $34M Series A as Truemed hit 3,000+ merchant partners and 3x YoY revenue.
Product & use cases
Truemed checkout and API let qualified wellness purchases process through HSA/FSA payment rails after appropriate medical necessity documentation — embedded at merchant checkout.
- Consumers buying gym, sleep, and nutrition products with HSA/FSA dollars
- Merchants increasing conversion by accepting tax-advantaged payments
- Employers enhancing preventive benefits without changing core health plans
Key facts
- Series A (Dec 2025): $34M led by a16z Bio+Health; Bessemer, BoxGroup participated (PR Newswire)
- 3,000+ merchant partners; ~3x YoY revenue growth cited (a16z)
- HSA/FSA payments for evidence-based preventive health products
- Letter of Medical Necessity workflow for eligible purchases
Funding history (newest first)
Series A
2025-12 $34MSource: Read source · prnewswire.com
Investors in our directory
Funds linked from Truemed's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Merchant network scale (3,000+ partners) plus compliance workflow for LMNs — hard to replicate quickly for new entrants.
HSA/FSA rules are complex and change-sensitive. Truemed's growth depends on merchant ROI proof and regulatory clarity on eligible preventive categories.
-
Flex (HSA/FSA payments) direct
Competing HSA/FSA checkout integrations.
-
Traditional HSA administrators incumbent
Bank-held HSAs without merchant-embedded checkout.
-
Post-tax wellness spend alternative
Default consumer behavior Truemed tries to shift.
Notable stories
- Truemed turned tax-advantaged HSAs into a growth lever for DTC wellness brands — a16z Bio+Health led Series A at 3,000 merchants when most shoppers still paid post-tax (PR Newswire, Dec 2025).
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Truemed's financing or category context.
FAQs about Truemed
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.